Stoke Therapeutics develops medicines that aim to increase protein production from healthy genes, using its TANGO (Targeted Augmentation of Nuclear Gene Output) RNA-based platform. The approach targets genetic diseases caused by insufficient protein levels, rather than replacing or editing genes outright. Its lead programs address severe neurological conditions, including Dravet syndrome, a rare and difficult-to-treat form of epilepsy. The company primarily serves patients with monogenic disorders for which few disease-modifying options exist.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q2 2025 | 13.8 | — | -23.5 | — |
| Q3 2025 | 10.6 | — | -38.4 | — |
| Q4 2025 | 1.4 | — | -57.9 | — |
| Q1 2026 | 6.2 | — | -50 | — |
| Q2 2026 | 9.3 | -32.5% | -61.6 | — |
All markets — KeepWinning global stock screener
Other companies on Nasdaq: Generate Biomedicines, Inc. (GENB), Cracker Barrel Old Country Store, Inc. (CBRL), ConnectOne Bancorp, Inc. (CNOB), OceanFirst Financial Corp. (OCFC), Maze Therapeutics, Inc. (MAZE), Safety Insurance Group, Inc. (SAFT)